Why is Liquidia stock plunging? Yutrepia patent case explained
Shares of Liquidia Corporation plunged nearly 50% on September 30 after a US federal court ruled against the company in its long-running patent dispute with United Therapeutics. The ruling puts fresh pressure on the commercial outlook for Liquidia’s key drug, Yutrepia. (Sources: Reuters, Benzinga) Liquidia Stock Plunges Nearly 50%
Shares of Liquidia Corporation plunged nearly 50% on September 30 after a US federal court ruled against the company in its long-running patent dispute with United Therapeutics. The ruling puts fresh pressure on the commercial outlook for Liquidia’s key drug, Yutrepia. (Sources: Reuters, Benzinga) Liquidia Stock Plunges Nearly 50%
What's Your Reaction?
